SAN

74.11

-0.78%↓

SRT3

223.65

-1.15%↓

ORNBV.FI

68.5

+3.4%↑

PHMA

95.6

-1.49%↓

DRW3

90.65

+2.03%↑

SAN

74.11

-0.78%↓

SRT3

223.65

-1.15%↓

ORNBV.FI

68.5

+3.4%↑

PHMA

95.6

-1.49%↓

DRW3

90.65

+2.03%↑

SAN

74.11

-0.78%↓

SRT3

223.65

-1.15%↓

ORNBV.FI

68.5

+3.4%↑

PHMA

95.6

-1.49%↓

DRW3

90.65

+2.03%↑

SAN

74.11

-0.78%↓

SRT3

223.65

-1.15%↓

ORNBV.FI

68.5

+3.4%↑

PHMA

95.6

-1.49%↓

DRW3

90.65

+2.03%↑

SAN

74.11

-0.78%↓

SRT3

223.65

-1.15%↓

ORNBV.FI

68.5

+3.4%↑

PHMA

95.6

-1.49%↓

DRW3

90.65

+2.03%↑

Strona główna・Stock List・Vetoquinol SA

Vetoquinol SA

Closed

SectorHealthcare

77.1 1.31

Buy Sell

Overview

Share price change

24h

Current

Min

76.5

Max

77.1

Key metrics
By Trading Economics
Income	25M
Sales	10M 268M
P/E Sector Avg	14.588 49.8
Dividend yield	1.21
Profit margin	9.734
Employees	2,497
EBITDA	252M 301M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+44.55% upside

Dividends
By Dow Jones
Dividend yield Sector Avg	1.21% 2.25%

Market Stats
By TradingEconomics
Market Cap	-57M 878M
Previous open	75.79
Previous close	77.1

News Sentiment

By Acuity

50%

136 / 347 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

72.6 / 75.1 Support & Resistance

Vetoquinol SA Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

7 maj 2026, 23:58 UTC

Earnings

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7 maj 2026, 22:57 UTC

Earnings

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7 maj 2026, 23:52 UTC

Earnings

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7 maj 2026, 23:45 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7 maj 2026, 23:39 UTC

Market Talk

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7 maj 2026, 23:28 UTC

Market Talk

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7 maj 2026, 23:11 UTC

Earnings

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7 maj 2026, 23:06 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7 maj 2026, 23:05 UTC

Earnings

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7 maj 2026, 23:04 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7 maj 2026, 23:03 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7 maj 2026, 23:03 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7 maj 2026, 23:02 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7 maj 2026, 23:00 UTC

Market Talk

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7 maj 2026, 22:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 maj 2026, 22:45 UTC

Market Talk

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7 maj 2026, 22:42 UTC

Earnings

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7 maj 2026, 22:33 UTC

Earnings

Acquisitions, Mergers, Takeovers

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 maj 2026, 22:32 UTC

Earnings

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7 maj 2026, 22:31 UTC

Earnings

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7 maj 2026, 22:31 UTC

Earnings

Macquarie: 68% of FY Income From International >MQG.AU

7 maj 2026, 22:30 UTC

Earnings

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7 maj 2026, 22:30 UTC

Earnings

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7 maj 2026, 22:29 UTC

Earnings

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7 maj 2026, 22:28 UTC

Earnings

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7 maj 2026, 22:28 UTC

Earnings

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7 maj 2026, 22:27 UTC

Earnings

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7 maj 2026, 22:27 UTC

Earnings

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7 maj 2026, 22:26 UTC

Earnings

Macquarie to End Share Buyback Extended in November>MQG.AU

7 maj 2026, 22:25 UTC

Earnings

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Peer Comparison

Price change

Vetoquinol SA Forecast

Price Target

By TipRanks

44.55% upside

12 Months Forecast

Average 110 EUR 44.55%

High 110 EUR

Low 110 EUR

Based on 1 Wall Street analysts offering 12 month price targets forVetoquinol SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Vetoquinol SA - Dist in the past 3 months.

Technical Score

By Trading Central

72.6 / 75.1Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

136 / 347 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Vetoquinol SA

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.